233 related articles for article (PubMed ID: 33745894)
1. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression.
Joshi N; Hajizadeh F; Ansari Dezfouli E; Zekiy AO; Nabi Afjadi M; Mousavi SM; Hojjat-Farsangi M; Karpisheh V; Mahmoodpoor A; Hassannia H; Dolati S; Mohammadi H; Yousefi M; Jadidi-Niaragh F
Life Sci; 2021 Jun; 275():119369. PubMed ID: 33745894
[TBL] [Abstract][Full Text] [Related]
2. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo.
Salehi Khesht AM; Karpisheh V; Sahami Gilan P; Melnikova LA; Olegovna Zekiy A; Mohammadi M; Hojjat-Farsangi M; Majidi Zolbanin N; Mahmoodpoor A; Hassannia H; Aghebati-Maleki L; Jafari R; Jadidi-Niaragh F
Int J Biol Macromol; 2021 Sep; 186():849-863. PubMed ID: 34245737
[TBL] [Abstract][Full Text] [Related]
3. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA.
Han L; Tang C; Yin C
Biomaterials; 2015 Aug; 60():42-52. PubMed ID: 25982552
[TBL] [Abstract][Full Text] [Related]
5. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
[TBL] [Abstract][Full Text] [Related]
6. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
7. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
8. Blockade of HIF-1α and STAT3 by hyaluronate-conjugated TAT-chitosan-SPION nanoparticles loaded with siRNA molecules prevents tumor growth.
Budi HS; Izadi S; Timoshin A; Asl SH; Beyzai B; Ghaderpour A; Alian F; Eshaghi FS; Mousavi SM; Rafiee B; Nikkhoo A; Ahmadi A; Hassannia H; Ahmadi M; Sojoodi M; Jadidi-Niaragh F
Nanomedicine; 2021 Jun; 34():102373. PubMed ID: 33667724
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat.
Cheng D; Cao N; Chen J; Yu X; Shuai X
Biomaterials; 2012 Feb; 33(4):1170-9. PubMed ID: 22061491
[TBL] [Abstract][Full Text] [Related]
11. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
12. [Small interfering RNA targeting STAT3 enhances antitumor activity of doxorubicin].
Wang TX; Wang YY; Zhang ZQ
Yao Xue Xue Bao; 2013 Jan; 48(1):52-8. PubMed ID: 23600141
[TBL] [Abstract][Full Text] [Related]
13. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells.
Dong DW; Xiang B; Gao W; Yang ZZ; Li JQ; Qi XR
Biomaterials; 2013 Jul; 34(20):4849-59. PubMed ID: 23541420
[TBL] [Abstract][Full Text] [Related]
14. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
[TBL] [Abstract][Full Text] [Related]
15. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
[TBL] [Abstract][Full Text] [Related]
16. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effect of silencing STAT3 gene with short hairpin RNA mediated by polyamidoamine dendrimers on growth of prostate cancer].
Zhao WM; Xiu YC; Xu Y; Wang YM; Cheng ZK; Yu Q; Kong DL
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):575-9. PubMed ID: 18210874
[TBL] [Abstract][Full Text] [Related]
18. Hyperbranched-hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy.
Jia HZ; Zhang W; Zhu JY; Yang B; Chen S; Chen G; Zhao YF; Feng J; Zhang XZ
J Control Release; 2015 Oct; 216():9-17. PubMed ID: 26272764
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
[TBL] [Abstract][Full Text] [Related]
20. Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression.
Salimifard S; Karoon Kiani F; Sadat Eshaghi F; Izadi S; Shahdadnejad K; Masjedi A; Heydari M; Ahmadi A; Hojjat-Farsangi M; Hassannia H; Mohammadi H; Boroumand-Noughabi S; Keramati MR; Jadidi-Niaragh F
Life Sci; 2020 Nov; 260():118423. PubMed ID: 32941896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]